- Home
- AYTU vs CANF Comparison
AYTU vs CANF Comparison
Compare AYTU & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- CANF
- Stock Information
- Founded
- AYTU N/A
- CANF 1994
- Country
- AYTU United States
- CANF Israel
- Employees
- AYTU N/A
- CANF N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- CANF Health Care
- Exchange
- AYTU Nasdaq
- CANF Nasdaq
- Market Cap
- AYTU 23.0M
- CANF 9.6M
- IPO Year
- AYTU N/A
- CANF N/A
- Fundamental
- Price
- AYTU $2.18
- CANF $0.44
- Analyst Decision
- AYTU Strong Buy
- CANF Strong Buy
- Analyst Count
- AYTU 3
- CANF 2
- Target Price
- AYTU $9.17
- CANF $14.50
- AVG Volume (30 Days)
- AYTU 181.5K
- CANF 280.3K
- Earning Date
- AYTU 11-13-2025
- CANF 11-27-2025
- Dividend Yield
- AYTU N/A
- CANF N/A
- EPS Growth
- AYTU N/A
- CANF N/A
- EPS
- AYTU N/A
- CANF N/A
- Revenue
- AYTU $66,382,000.00
- CANF $560,000.00
- Revenue This Year
- AYTU N/A
- CANF $461.72
- Revenue Next Year
- AYTU $29.12
- CANF N/A
- P/E Ratio
- AYTU N/A
- CANF N/A
- Revenue Growth
- AYTU 1.84
- CANF N/A
- 52 Week Low
- AYTU $0.95
- CANF $0.43
- 52 Week High
- AYTU $2.82
- CANF $2.50
- Technical
- Relative Strength Index (RSI)
- AYTU 46.96
- CANF 24.09
- Support Level
- AYTU $2.23
- CANF $0.42
- Resistance Level
- AYTU $2.31
- CANF $0.49
- Average True Range (ATR)
- AYTU 0.12
- CANF 0.03
- MACD
- AYTU -0.01
- CANF -0.00
- Stochastic Oscillator
- AYTU 17.54
- CANF 2.21
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).